DISEASE SCANNER
Global Incurable Diseases Tracker
Amyloidosis
A group of diseases characterized by abnormal protein (amyloid) deposition in tissues and organs, disrupting normal function. Can affect heart, kidneys, liver, spleen, nervous system, and digestive tract. Multiple types including AL (light chain), ATTR (transthyretin), and AA (secondary) amyloidosis.
50.0K
15
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Tissue biopsy with Congo red staining
- 2Mass spectrometry
- 3Bone marrow biopsy (AL)
- 4Cardiac MRI
- 5Echocardiogram
- 6Genetic testing
- 7Serum free light chains
- 8NT-proBNP, troponin
Prognosis
Variable by type and organ involvement. AL amyloidosis: median survival 12-18 months without treatment, 4+ years with modern therapy. ATTR-CM: tafamidis improves survival. Early diagnosis critical.
Prevention
- No primary prevention for most types
- Genetic counseling for hereditary forms
- Early treatment of underlying conditions
- Regular monitoring for at-risk families
Research Status
Treatments vary by type: AL amyloidosis - chemotherapy, stem cell transplant, daratumumab. ATTR amyloidosis - tafamidis stabilizer, patisiran gene silencing. Liver transplant for hereditary ATTR. Supportive care for organ failure.
Affected Countries
Sources
- https://www.cdc.gov/
- https://www.hematology.org/education/patients
- https://www.ncbi.nlm.nih.gov/books
- https://rarediseases.org/rare-diseases
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.